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ABSTRACT
IDENTIFYING AGGREGATIBACTER ACTINOMYCETEMCOMITANS
PERIODONTAL ANTIGENS BY IMMUNOSCREENING
Gerald B. Pevow
May 4, 2012
Periodontitis is a chronic, destructive inflammatory disease of the supporting
tissues of the teeth with a high prevalence among adults. While the complete
pathogenesis of periodontitis remains unclear, it is initiated and sustained by dental
plaque containing pathogens such as Porphyromonas gingivalis, Aggregatibacter
actinomycetemcomitans, Bacteroides forsythus, and Prevotella intermedia.

Our hypothesis is that multiple antigens are recognized by human antibodies, and
antigens can be identified by use of a genomic expression library. We developed an
unbiased global approach to define A. actinomycetemcomitans protein antigens that elicit
humoral immune responses and developed a screening method to identify periodontal
antigens. We identified 19 unique antigens, 17 of which have not been studied in A.
actinomycetemcomitans

Future studies should 1) use additional human sera to identify additional antigens,
2) elucidate the role of identified antigens, and 3) determine how A.
actinomycetemcomitans antigen-antibody profiles relate to disease progression.
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INTRODUCTION

Periodontitis is a chronic, destructive, multifactorial inflammatory disease of the
supporting tissues of the teeth with a high prevalence among the adult population.
Whereas the complete pathogenesis and mechanism of periodontal disease progression
remains unclear, it is initiated and sustained by dental plaque containing bacterial
pathogens. Some of the most commonly investigated periodontal pathogens include
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Bacteroides
forsythus, and Prevotella intermedia (Lovegrove, 2004).
Plaque-induced periodontal diseases are mixed infections associated with
relatively specific groups of oral bacteria (Armitage, 2009, Lovegrove, 2004, Socransky,
2002). Patient susceptibility and disease progression is highly variable, depending on
both environmental factors and the host responses to periodontal pathogens (Zambon,
1996; Komman, 1997; Van Dyke, 2005; Darveau, 2009). Risk factors for periodontal
disease include but are not limited to smoking, age, diabetes mellitus, stress (depression,
anxiety, job or financial strain), gender, medication, socio-economic status and HIV
infection (Ng, 2006; Armitage, 2003, Corbet 2011).
To arrive at a periodontal diagnosis, clinicians observe the presence or absence of
signs of inflammation such as 1) bleeding on probing; 2) probing depths; 3) extent and
pattern of loss of clinical attachment and bone; 4) patient's medical and dental histories;
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and 5) presence or absence of additional clinical indicators such as pain, ulceration, and
the amount of plaque and calculus. Inflammation without observable connective tissue
attachment loss is termed gingivitis while inflammation with attachment loss is termed
periodontitis (Armitage, 2010).
Periodontitis is a common dental disorder. However, estimates of the exact
prevalence of periodontitis in the U.S. and worldwide vary due to inconsistent disease
definition and study methodology (Costa, 2009). If periodontitis is defined as the
identification of at least one site with Clinical Attachment Loss I (CAL) of 2': 2 mm,
around 80% of all adults are affected, and around 90% of those aged 55 to 64 (Centers for
Disease Control, 1997). However, if the case definition is at least one site with CAL of 2':
4 mm, the prevalence in those aged 55 to 64 drops to around 50%, and with a case
definition of CAL 2': 6 mm, prevalence is less than 20% (Burt, 2005; Baelum, 2003).
Despite efforts by the Center for Disease Control and Prevention and the American
Academy of Periodontology to develop consensus, the discussion of definitions of
periodontal diseases and periodontitis continues (Corbet, 2011; Meisel, 2009).
Nevertheless, by any definition, a large portion of the U.S. population suffers from
periodontitis.
Periodontitis is caused by inflammation and infection of the tissues that support
the teeth and is characterized by the loss of attachment between the teeth and the
surrounding tissues. It is classified as chronic or aggressive periodontitis based on the
differing rates of loss of attachment of the teeth and the patient's age and medical status
(Armitage, 1999; Armitage, 2010; Schaudinn, 2009). Chronic periodontitis, the most
I Clinical attachment loss (CAL) is the predominant clinical manifestation and determinant of periodontitis.
It is calculated as the clinician's probing depth measurement plus hislher gingival margin level
measurement.
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common type of periodontitis, is typically a slowly progressing disease that emerges
clinically in adulthood and continues throughout life. By contrast, aggressive
periodontitis is less common than chronic periodontitis and principally affects young
people (Armitage, 2003; Armitage, 2010).
Further, chronic and aggressive periodontitis is characterized by extent (localized
or generalized) and severity (slight, moderate, and severe). By definition, localized
periodontitis affects less than 30% of sites while generalized periodontitis affects 30% or
more sites (Savage, 2009). Also by definition, severity is measured by clinical attachment
loss (CAL) as follows: Slight = 1-2mm, Moderate

= 3-4 mm, and Severe ~ 5 mm

(Armitage, 2003; Armitage, 2010).
The disorder is initiated by dental plaque, a microbial biofilm. Like other biofilm
infections, periodontitis is refractory to antibiotic agents and host defenses because the
causative microbes live in complex communities that persist despite challenges. Oral
health or disease depends on the interface between the host and the microbial community
as a whole. Further, both the pathogenicity of specific microbes and the community
within which they reside are important to study (Jenkinson, 2005; Kuramitsu, 2007;
Schaudinn, 2009).
Bacteria play an essential role in the etiology of periodontal disease. Over 700
bacterial species have been identified in the oral cavity and nearly 300 species have been
cultured and found to contribute to the biofilm of the periodontal pocket (Dewhirst, 2010;
Jenkinson, 2005; Loesche, 2001; Nibali, 2009; Paster, 2001; Picolos, 2005). However,
the direct involvement of each individual microbe in pathogenesis remains unclear. Some
of the most commonly investigated periodontal pathogens include Porphyromonas
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gingivalis, Aggregatibacter actinomycetemcomitans, Bacteroides forsyth us, and
Prevotella intermedia based on earlier work associating bacterial species with severity of

disease (Haffajee, 1994).
Aggregatibacter actinomyctemcomitans, formerly Actinobacillus
actinomycetemcomitans, is a gram-negative, facultative anaerobic coccobacillus

bacterium that colonizes the oral cavities of humans (Norskov-Lauitsen, 2006; Henderson
2011). Several studies have shown that A. actinomycetemcomitans is significantly
associated with both aggressive periodontitis and chronic periodontitis (Ebersole, 1995a;
Zambon, 1996; Loesche, 2001; Cortelli, 2005; Rylev, 2008). The association is clearly
greatest with aggressive periodontitis. However, strong associations have been reported
for A. actinomycetemcomitans with chronic periodontitis patients, 74% (Choi, 2000);
50% (Kuboniwa, 2004); >75% (Rodrigues, 2004); 30% (Slots, 1990); 60% (Sixou,
1991); 75% (Savitt, 1991); 28% (Sandholm, 1987); 55% (Flemmig, 1996).
Additional evidence linking A. actinomycetemcomitans with periodontitis is that
there is a clear immune response of the host to A. actinomycetemcomitans infection
(Kinane, 1999; Apatzidou, 2004). Further, certain anti-A. actinomycetemcomitans serum
antibodies appear to protect patients from disease (Flemmig, 1996; Lamster, 1998). Such
data have led reviewers to generally conclude that A. actinomycetemcomitans is likely a
periodontal pathogen in humans (Zambon, 1996; Kinane, 2000b; Kinane, 2001a;
Loesche, 2001; Henderson, 2002; Mombelli, 2002; Henderson, 2003; Lovegrove, 2004).
This conclusion is supported by experimental evidence in animal models including
miniature pigs, dogs, rats, and mice which demonstrates that A. actinomycetemcomitans
does cause periodontal disease (Freire, 2011; Fine, 2009; Oz, 2011).
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The onset and severity of periodontal disease is largely controlled by the
effectiveness of the immune response of the patient to the oral pathogens. As contributors
to the immune response, several lines of evidence indicate that peripheral serum
antibodies are relevant to disease progression: Immunization against A.
actinomycetemcomitans bacteria can attenuate infection-induced periodontitis-like

disease, and total serum antibody levels correlate with decreased severity of disease
(Casarin, 2010; Rams, 2006).
However, high serum antibody titers do not always prevent disease. Thus,
analysis of specific host antibodies to specific bacterial antigens is likely to be more
informative than gross analysis of total serum immunoglobulin levels. This is the premise
of the present work and from which we developed the project hypothesis: Antibodies to
certain A. actinomycetemcomitans bacterial proteins are very highly associated with the
severity of, and response to, treatment of periodontal disease.
Several such studies of specific host antibodies have investigated one or very few
antibody/antigen relationships at a time. These studies indicate the clinical significance of
serum antibodies. However, it remains unclear whether some groups of antibodies elicit
better protection than others.
The purpose of this study was to identify immunoreactive A.
actinomycetemcomitans proteins by use of an unbiased genomic DNA lambda phage

expression library. The method allows for a global screening approach to identify all
protein epitopes encoded on the bacterial genome that may elicit a human antibody
response. Bacterial protein antigens that elicit a humoral response can then be further
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studied and associations drawn between the immune response and clinical indices. The
four main goals of this research project are to:
1. create bacteriophage lambda genomic expression libraries expressing peptides
encoded on the A. actinomycetemcomitans genome,
2. develop the immunoscreening method as a broad approach to find novel bacterial
antigens,
3. optimize the immunoscreening method for this project and immunoscreen whole
celllysates from A. actinomycetemcomitans JP2, and
4. identify and characterize A. actinomycetemcomitans antigens obtained through the
optimized immunoscreening method.

While the research used an unbiased global approach to define novel bacterial
protein antigens that elicit humoral immune responses, there are other methods to identify
novel protein antigens, most notably IVIAT, In Vivo Induced Antigen Technology
(Handfield, 2000; Cao 2004). IVIAT also uses bacterial genomic DNA expression
libraries, supporting the utility of such an approach. However, the goal of the IVIA T
approach is the opposite of the goal of this research. IVIAT seeks to identify the
bacteria's response to living inside the host, whereas we seek to identify a major
component of the host's response to the bacteria. Further, the IVIAT technology requires
pooled sera and is not easily compatible with creation of microarrays.
A future goal for this project is to identify a discrete set of the most informative
antigen proteins for use as prognostic diagnostic indicators. Such indicators may be of
interest to determine whether the antibody profile of patients with gingivitis will develop
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periodontitis in the future. This is based on the idea that certain antigen-specific
antibodies confer protection from disease whereas other antigen-specific antibodies do
this poorly. A micro array would be a simple approach to identify whether a given patient
has serum antibodies that correlate with a protective response. Arranged in a micro array,
the antigens have the potential for broad use as a prognostic diagnostic tool in the setting
of a clinical lab.
Further, such antigenic proteins may be useful as a vaccine to confer resistance
against periodontal disease. If certain A. actinomycetemcomitans antigenic proteins cause
an immune response in humans that protects against periodontitis, those proteins could
then be used as a vaccine candidate to prevent disease.
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METHODS AND MATERIALS

Bacteriophage Lambda Genomic DNA Expression Libraries
The goal of this research is to identify bacterial proteins which are antigenic in
patients. This is done by using human sera to screen an unbiased bacterial genomic DNA
expression library. Libraries are collections of cloned DNA fragments. Ideally, they
contain a complete representation of genomic or cDNA sequences. They are commonly
"packaged" in bacteriophage vectors. Different library types have different utilities and
starting material. The most common types are cDNA libraries or genomic libraries.
cDNA libraries contain only complementary DNA molecules synthesized from
mRNA in a cell. Because cDNA libraries are copied directly from mRNA molecules they
will only contain DNA representing mature mRNAs, i.e. intron sequences are not present.
cDNA libraries have been essential for isolation of novel mRNAs. However, they
typically over-represent abundant RNAs and may lack rare mRNAs. Also, cDNA
libraries lack information about enhancers, introns, and other regulatory elements found
in a genomic DNA library.
Genomic libraries contain random DNA fragments representing the entire genome
of an organism. Genomic libraries are useless for expression of eukaryotic genes since
these genes contain introns. However, bacterial genes lack introns. Use of bacterial
genomic DNA for an expression library provides a better representation of bacterial
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peptides than a bacterial cDNA library constructed from mRNAs since different mRNAs
are likely expressed during in vitro culture than in vivo. Hence, this approach is not
biased by the initial abundance of mRNAs. This research project takes advantage of the
extremely high gene density of the bacterial genome, which lacks introns, and the project
uses genomic libraries since bacterial genes expressed selectively in the oral cavity may
be severely under-represented in a cDNA library.
The first step in genomic library preparation is the isolation of large fragments of
chromosomal DNA (Figure 1). Extraction conditions should break open the cells to
release the DNA but should minimize the shearing of DNA into small pieces. Also
endogenous nuclease activity should be minimized in order to keep the DNA intact.
Once large fragments of DNA are isolated, they need to be cut into the right size
to be inserted into a vector. Not onlydo the fragments need to be sized correctly, but they
also need to cut the DNA randomly so that the library will contain a collection of
overlapping fragments. Such a collection ensures that all regions of the chromosome are
equally represented. The best way to accomplish this is to partially digest the DNA with
restriction endonucleases. Restriction digests not only cut DNA into the appropriate sizes,
but also generate fragments with sticky ends that allow for easy insertion into the vector
of choice. A restriction digest will leave some DNA fragments that are too large and
some that are too small to use in a library. Thus, upon completion of a restriction digest,
the appropriate sized fragments are fractionated by gel electrophoresis, cut from the gel
and then purified to isolate the fragments from the gel. Once the fragments of DNA are
isolated, they need to be inserted into a vector to generate the genomic library. The most
commonly used vectors for genomic libraries are lambda derivatives that have large
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Figure 1. Genomic DNA Library Construction

Target DNA

DNA Fragments
Digest w ith
Restriction Enzyme

~

,

~NA
~~ckaging,

recombination,
assembly

Phage

! !
Infect E. coli

Figure 1. Genomic DNA Library Construction. Target DNA is partially digested with a
restriction endonuclease resulting in overlapping DNA fragments of varying lengths.
DNA fragments are packaged and assembled in phage with each phage containing a
different DNA fragment. E. coli is spread on an agar plate and infected E. coli create a
plaque on the bacterial lawn. One phage infects one bacterium so each plaque represents
a unique DNA sequence.
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fragments that can be removed and substituted for equally large pieces of genomic DNA.
Excess lambda arms are added to restriction endonuclease-digested genomic DNA. The
sticky ends of the DNA fragments hybridize with the lambda arms and are subsequently
ligated together with DNA ligase. Finally, the DNA is packaged into lambda capsids,
resulting in lambda phages with random DNA inserts. The product is a library of many
thousands of recombinant lambda phage each containing a unique fragment of
chromosomal DNA.
Preliminary work used genomic DNA from A. actinomycetemcomitans strain
HK1651 (American Type Culture Collection) and a modified ATriplEx2 vector
(Clontech) that allows use of the EcoR1 site for making the library. HK1651 is serotype
b, based on its immune responses to surface antigens. Serotype b is the most prevalent A.
actinomycetemcomitans serotype in both aggressive and chronic periodontitis (Yang,
2004).

ATriplEx2 was initially used because it expresses in all three reading frames,
decreasing the number of screens necessary to immunoscreen the entire A.
actinomycetemcomitans genome. However, it did not appear to have the expression levels

necessary to provide a strong positive signal and clearly differentiate positive from
negative plaques. As such, all later work (and all results) used Lambda ZAP II
Expression Library and Gigapack Gold III packaging kit purchased from Stratagene
(USA). Further, A. actinomycetemcomitans strain lP2 cultures were received from the
laboratory of Dr. Don Demuth (University of Louisville) and used instead of HK 1651
genomic DNA. lP2, like HK 1651, is a well characterized serotype b strain.
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Partial Digestion of Genomic DNA
To give overlapping fragments, A. actinomyctemcomitans genomic DNA (5 Ilg)
was partially digested with 5 Units of TSP5091 restriction endonuclease (New England
Biolabs) for approximately 60 min. Tsp5091 is not sensitive to methylation and cuts at
the 4-base recognition sequence AATT leaving a 4 base 5'-overhang identical to the
EcoR 1 overhang on the vector. Since Tsp5091 cuts at a 4-nucleotide target, it is predicted
to cut random sequence DNA with a frequency of once every 256 bases.
Digestion was assessed by running an aliquot of digested DNA on 1% agarose gel
to verify generation of random length DNA fragments. Fragments from 400-1500 bp in
size were excised from the gel. The DNA was purified from the gel plugs using Qiagen
gel purification columns (Qiagen, USA).

Library Creation Using Lambda Bacteriophage Vector
Lambda Zap II arms (Stratagene, cat#236612), commercially EcoRI digested and
Calf Intestinal Alkaline Phosphatase treated, were added to the partially digested
A.actinomyctemcomitans DNA fragments inserts at a ratio of 1: 1 (500 ng arms to 500 ng

of DNA) to 3: 1. T4 DNA Ligase (New England Biolabs) was used, in a reaction volume
of 6 [lL, for an 18 hour incubation at 16°C to ligate lambda arms with the insert to form a
recombinant lambda phage-genomic DNA strand (Figure 2). The recombinant arms were
then packaged (ie. addition of phage protein coat) using a lambda packaging reaction,
Gigapack III Gold Packaging Reaction (Stratagene, cat#200206) for 2 hours at room
temperature. This phage packaging kit is capable of producing lx10 8 PFU/llg DNA.
Recombination efficiency was determined by measuring the loss of B-galactosidase
acti vity in recombinant phages. The host bacteria, XL 1-Blue MRF', was infected with the
12

packaging reaction and plated in the presence of IPTG and X-gal. Since phage that are
packaged in vitro are not very stable, half the library was immediately amplified and
stored at -80°C.
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Figure 2. Lambda Zap II Cloning Procedure

1.
2.

Construct DNA Library
Isolate Positive Clone

3.

Excise pBluescript Plasmid
Containing Cloned DNA Insert by
Co-Infection with Helper Phage

T1
~

t

limp'

T3

pBlut liptn

S

1 bp)

2

Oil

Figure 2. Lambda ZapII Cloning Procedure. Lambda ZAP vectors simplify the
construction of high-titer cDNA libraries and the characterization of inserted DNA. They
allow easy excision and recircularization of cloned insert DNA from lambda phage and
eliminate the need for subcloning procedures.
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Library Characterization
Libraries were characterized in order to assure a high representation of the
bacterial genome. Genomic DNA insert sizes were determined by restriction digests of
cloned inserts. The Lambda ZAP vector allows in vivo excision and recircularization of
cloned inserts to form a plasmid (phagemid) containing the cloned insert. Signals for
packaging the phagemid are contained within the f1 terminator origin DNA sequence and
permit the circularized DNA to be packaged and secreted from the E. coli. Once secreted,
the E. coli cells used for excision of the cloned DNA can be removed from the
supernatant by heat treatment. Once the packaged pBluescript DNA is mixed with fresh
E. coli cells and re-plated, DNA from minipreps of these colonies can be used for
analysis of insert DNA.
Details of this method are as follows: Plaques are cored from the agar plate and
transferred to a sterile microcentrifuge tube containing 500 III of SM buffer and 20 III of
chloroform. The microcentrifuge tube is vortexed to release the phage particles into the
SM buffer and incubated overnight at 4°C. Separately, 50 ml of XLI-Blue MRF' cells in
LB broth with supplements is cultured overnight at 30°C. The next day the cells are
centrifuged at 1000 x g and resuspended in MgS0 4 . 200 III of cells at an OD600 of 1.0
are combined with 1 III of the R408 helper phage and the phage from the plaque and
incubated at 37°C for 15 minutes to allow the phage to attach to the cells. 3 ml of LB
broth with supplements is added and incubated at 37°C overnight. Next, the tube is
incubated at 65-70°C for 20 minutes to lyse the lambda phage particles and the cells and
centrifuged at 1000 x g for 15 minutes to pellet the cell debris. The supernatant
containing the excised pBluescript phagemid packaged as filamentous phage particles is
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decanted into a sterile 14 ml round-bottom tube. 200 III of freshly grown XLI-Blue
MRF' cells are placed in two microcentrifuge tubes and 100 III of the phage supernatant
is added to one of the tubes and 10 III to the other microcentrifuge tube. The tubes are
incubated at 37°C for 15 minutes and plated on LB-ampicillin agar plates and incubate
overnight at 37°C. Colonies contain the pBluescript double-stranded phagemid with the
cloned DNA insert.
After isolating the excised plasmid DNA by miniprep (Qiagen), insert sizes and
numbers were determined by restriction analysis. Acceptable libraries had an average
insert size greater than 750 bp (3 times the average frequency of Tsp5091 sites), ensuring
overlapping fragments. The complexity of the library was calculated as the number of
plaques with inserts per llg of insert DNA (Ausubel, 2000). Phage infected bacteria were
plated at a density of about 4000 plaques per plate. Screening 50,436 plaques was
calculated to provide a 95% probability that every section of the genome is represented in
an expression clone, based on the size of the bacterial genome (2.1 Mb A.
actinomycetemcomitans ), the average size of the inserts, and the fraction of clones in the
correct orientation and reading frame (Sambrook, 1989). The probability of having any
given genomic DNA sequence in the A. actin library can be calculated from the equation

N

In(l-P)

In(l-f)

where P is the desired probability, f is the fractional proportion of the genome in a single
recombination, and N is the necessary number of recombinants. To achieve a 95%
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probability of having a given DNA sequence represented in a library of 750 bp fragments
of the 2.1 Mb A. actinomycetemcomitans genome N = InO.05/ln(1-75012.1 Mb) = 8,406
plaques. N is then multiplied by 3 to correct for reading frame and by 2 for orientation.
Thus, 8,406 plaques x 6 = 50,436 plaques are necessary to screen in order to have a 95%
probability of having any given DNA sequence in the library.
To characterize later libraries, PCR was conducted directly on phage particles to
determine the frequency and size of inserts. Clear plaques lacking B-gal activity were
picked and amplified using Amplifier forward and Amplifier reverse primers that span
the EcoRI insert site and yield a band of 160 bp when no insert is present. PCR products
were run on a 1.0% agarose gel, for size determination. Gel slices were purified using the
Qiagen PCR clean-up kit (Qiagen, US) and the PCR products were collected for further
analysis.
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Figure 3. peR Analysis of Inserts

600 bp
160 bp

600 bp

Figure 3. peR Analysis of Inserts. peR Analysis of Inserts. peR was conducted on
inserts using M13 primers for Lambda Zap II. Bands cut from digest were between 400
bp and 1500 bp. No inserts would give a fragment of approximately 160 bp. 2 out of the
10 fragments had no inserts (Lanes 1,5). 80% of fragments contained inserts of the
anticipated size range based on the partial digest of A. actinomycetemcomitans genomic
DNA.
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Immunoscreening Genomic DNA Lambda Phage Expression Libraries
Analyzing Serum Pools by Western Blotting
Eleven human serum samples (Innovative Research, Southfield, MI) were prescreened to identify highly immunogenic serum by western blotting of bacterial proteins.
A western blot is an analytical technique used to detect specific proteins in a given
sample. It uses gel electrophoresis to separate proteins that are then transferred to a
membrane. Membranes are subsequently probed using antibodies specific to the target
protein.
For the western blot analysis of individual serum antibody responses to oral
bacteria, liquid cultures of A. actinomycetemcomitans, P. gingivalis and E. coli strain
XLl- Blue were centrifuged to pellet bacteria. The resulting pellets were washed and
suspended in 100 !!L of LB. The suspensions were then boiled for 15 min at 98°C to lyse
the bacteria. Lysates were quantified using a Nanodrop (Nanodrop Technologies, USA)
by absorbance at 280 nm wavelength. The bacterial proteins were separated on a 20%
polyacrylamide gel (NuSEP, USA) by gel electrophoresis and transferred to a PVDF
membrane. After blocking with a 5% milk-TBST blocking solution (25 mM Tris, 140
mM NaC!, 3 mM KCI, 1.0% Tween-20, pH 8.0), the membranes were cut into strips with

each of the three bacteriallysates on each strip. Strips were then probed overnight at 4°C
with a 1:500 dilution of human serum, purchased commercially from Innovative
Research, Inc. (Southfield, MI) and blocking buffer. Strips were subsequently washed
liberally with TBST and incubated for 1 hour at room temperature with goat anti-human
total Ig horseradish peroxidase (HRP) conjugated secondary antibody (Southern Biotech,
USA) at a dilution of 1:5000 in blocking buffer. Bound antibodies were visualized by the
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addition of DAB/CN (Pierce, USA). Chloronaphthol (CN) and diaminobenzidine (DAB)
are chromogenic peroxidase substrate compounds combined in a single, stable, lOX stock
solution. The CNIDAB solution produces an intense dark black precipitate at sites of
bound HRP-conjugated antibodies on probed blots. This identified sera exhibiting a high
titer of anti- A. actinomyctemcomitans antibodies. Three sera were combined for
screening the genomic expression library.

Immunoscreening A. actinomycetemcomitans Genomic DNA Libraries
Once a library has been constructed, a robust assay is needed to detect and isolate
the few clones containing antigens out of the millions of clones in the library.
Identification of a novel antigen involves the following steps: titering the library to
determine the PFU/ml (plaque forming units per ml of library stock), primary plating of
the library, preparing filters of phage plaques, screening of filters with human serum,
secondary screening, tertiary screening, preparation of DNA, and subcloning plus
sequencing of A. actinomycetemcomitans inserts.
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Figure 4. Immunoscreening Technique

Plate with library
Grow colonies or plaques
Some clones will contain
antigenic proteins

Put membrane on plate
Mark orientation of membrane on plate
Remove membrane from plate

Transfer agar to tube

Wash and block membrane
Add pooled serum
Add secondary Ab and detect

Figure 4. Immunoscreening Technique. A. actinomycetemcomitans genomic DNA library
is incubated with the growth culture of excess E. coli bacteria and plated to yield
approximately 2000-4000 plaques. The plaques appear on a lawn of bacteria whereby
each plaque represents a unique genomic DNA sequence of A. actinomycetemcomitans.
A nitrocellulose filter is placed onto the agar plate and by capillary action the plaques are
replicated on the nitrocellulose. A. actinomycetemcomitans antigens of interest are then
detected using an immune detection protocol.
21

Once titered, an appropriate amount of the bacteriophage lambda library is
incubated with the growth culture of excess E. coli bacteria. The bacteriophage infect the
E. coli and the cells are subsequently spread on agar plates. Plaques which contain the

debris from the lysed bacteria including the highly expressed A. actinomycetemcomitans
peptide (antigen), appear on the lawn of bacteria whereby one phage creates one plaque,
and each plaque represents a unique genomic DNA sequence of A.
actinomycetemcomitans. For immunoscreening, a library of 2000 to 4000 plaque-forming

units (PFU) was plated on each petri dish. For each screening, 10-15 petri dishes were
grown to give approximately 24,000 plaques total.
As the plaques grow, the lambda bacteriophage lyse the adjacent infected cells.
Each plaque expresses a high concentration of the peptide cloned into that phage. A
nitrocellulose filter is placed onto the agar plate and by capillary action the plaques are
replicated on the nitrocellulose.
An immune detection protocol is then used to detect the antigens of interest.
Antigens in different plaques immobilized on nitrocellulose membranes are detected with
human antibodies in a three-step process. Nitrocellulose membranes are placed into
individual petri dishes and diluted serum from three pooled patient samples is added to
each dish. Antibodies in the human serum are termed primary antibodies, and will bind to
those antigens on the membranes that the antibodies recognize. Since serum presumably
contains many different antibodies, it is likely that on an individual plate containing
approximately 2000 unique clones of A. actinomycetemcomitans antigens, that several
different antibodies will recognize different clones. This means that there will likely be
one or two antibody/antigen reactions on each membrane.
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In a second step, a secondary antibody-horseradish peroxidase (HRP) conjugate,

which recognizes general features of all human antibodies, is added to find locations
where the primary antibody is bound. In the third step, HRP, the enzyme conjugated to
the secondary antibody, catalyzes a colorimetric reaction when the appropriate substrate
is added, resulting in the deposition of colored product on the membrane at the individual
immunoreactive plaque. This color provides a visual indication of potential primary
antibody recognition. Positive, reactive plaques are identified, picked from the agar
plates, and preserved.
Because of the density of the plates, the wet surface of the plates, and the
difficulty in picking individual plaques, preserved plaques may contain some
contaminating phage. To decrease the likelihood of contamination and to confirm that a
positive plaque was picked, a secondary and tertiary screening is performed. In particular,
the tertiary screening is conducted at a low enough plaque density to ensure that the final
preserved plaque isolate is homogenous in nature.
Once screenings have been completed, each preserved, lambda phage containing
tertiary plaque is converted into a plasmid. By sub cloning the A. actinomyctemcomitans
insert from the lambda phage containing plaque into a plasmid vector, the positive A.

actinomyctemcomitans gene sequence is preserved and is more easily manipulated for
future studies.
Details of the above screening process are as follows: Phage infected bacteria
were plated at a density of 2000 to 4000 plaques per plate. IPTG soaked nitrocellulose
membranes were placed on each plate and the plates were incubated for 14 hours at 37°C.
Membranes were removed and washed in TBST-5% milk for 2 hours.
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Membranes were probed overnight with pooled human sera diluted 1:500 in 5%
milk in TBST. Goat anti-human total Ig human horse radish peroxidase (HRP)
conjugated secondary antibody (Southern Biotech, USA) were used to identify human
serum Ig bound plaques. Secondary antibodies were incubated with the membranes for 1
hour. To visualize reactive plaques, chloronapthol (CN) or DABICN (Pierce, USA) was
added to form a colored precipitate reaction. Plaques corresponding to the colored
reactive spots on the membranes were picked using disposable glass Pasteur pipettes.
Recombinant clones were purified through repeated plating, serum screenings, and
picking of reactive plaques.

Identifying and Characterizing A. actinomyctemcomitans Antigens
Each plasmid generated from identified immuno-positive tertiary plaques was
sequenced to identify the proteins expressed. Purified phage clones were amplified and
the pBluescript plasmid with the insert was excised following manufacturer's protocols.
Plasmid clones were sequenced at the University of Louisville Nucleic Acids Core
facility. pBluescript forward and reverse sequencing primers were provided to the Core
facility for sequencing and to confirm correct insert orientation.

Sequence Identification
A. actinomycetemcomitans clone sequences were compared to the published

genome using the Basic Local Alignment Search Tool (BLAST) on the lCVI website
(cmr.jcvi.org), on the ORALGEN website (www.oralgen.lanl.gov) or the NIH website
(blast.ncbi.nlm.nih.gov). The sequences of the insert DNA and 7 codons upstream of the
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EcoRI insert site were compared to the databases to identify A. actinomycetemcomitans
genes encoded within the insert. DNA inserts disrupt the coding sequence for

~

galactosidase since they are inserted within that sequence. Peptides are expressed as a
fusion protein with the first 7 amino acids of ~-galactosidase. This ensures the presence
of an initiator methionine. However, it also means that only one reading frame can be
expressed. The BLASTx option was utilized to ensure that the insert was in the correct
reading frame. Since a group of three nucleotides code for a single peptide, a totally
different polypeptide can be transcribed depending on whether reading starts with the
first, second, or third nucleotide. BLASTx (Basic Local Alignment Search Tool) is used
to compare a newly determined DNA sequence against already existing sequences in the
NCBI non redundant protein database.
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RESULTS

Genomic DNA Lambda Expression Library Creation
The steps in the creation of the A. actinomycetemcomitans Genomic DNA
Lambda Expression Library are as follows:
1. Partial Digestion of A. actinomycetemcomitans genomic DNA
2. Ligation and packaging of the Genomic DNA Lambda Expression Library
3. Characterization of the A. actinomycetemcomitans Expression Libraries

Partial Digestion of A. actinomycetemcomitans Genomic DNA
A. actinomyctemcomitans genomic DNA (0.4 Ilg) was partially digested with

varied amounts of TSP5091 restriction endonuclease to identify the optimal ratio of
enzyme to DNA. Digestion was assessed by running an aliquot of digested DNA on 1%
agarose gel to verify generation of random length DNA fragments. Based on the results
in Figure 5, the ideal ratio of TSP5091 to A. actinomyctemcomitans DNA was 3.3
Units/ug DNA. Subsequently, a preparative digestion was done using 16.5 U TSP5091
and 5 Ilg genomic DNA. The entire reaction was fractionated on an agarose gel.
Fragments from 400-4000 bp in size were excised from the gel. The gel plugs were
purified using Qiagen gel purification columns (Qiagen, USA). The pooled DNA was
used for library construction.
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Figure 5. Analytical and Preparative Partial Digests of A.a. Genomic DNA
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Figure 5. Analytical and Preparative Partial Digests of A. actinomycetemcomitans
Genomic DNA. A. For analysis, A. actinomyctemcomitans genomic DNA (0.4 Jlg) was
partially digested with TSP5091 restriction endonuclease. Tube 1 contains 4 Units of
TSP5091. Tubes 2-5 were serial dilutions as follows: 1.33 U, .44 U, .15 U, .07 U).
Conditions were optimized by running the partial digestions on 1% agarose gels. Based
on the results, the ideal ratio of TSP5091 to A. actinomyctemcomitans genomic DNA was
3.3 U/ug DNA (Lane 2). B. For library construction, 5 ug of A. actinomyctemcomitans
genomic DNA was partially digested with 16.5 Units of TSP5091 restriction
endonuclease. Fragments from 400-1500 bp in size were excised from the gel, and
purified using Qiagen gel purification columns (Qiagen, USA).
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Ligation and Packaging of Genomic DNA AExpression Library
Commercially available Lambda Zap II arms (Stratagene) were added to the
partially digested A.actinomyctemcomitans DNA fragment with T4 DNA Ligase (New
England Biolabs) and incubated overnight to ligate lambda arms to the insert. The
overhang left by the TSP5091 digestion matches and ligates with the EcoR 1 overhangs
on the ends of the lambda arms. The resultant recombinant lambda phage-genomic DNA
strands were then packaged by the addition of phage coat proteins using a lambda
packaging reaction, Gigapack III Gold Packaging Reaction (Stratagene).

Characterization of the A. actinomycetemcomitans Expression Libraries
Recombination efficiency was determined by measuring the loss of ~
galactosidase activity in recombinant phages. Lambda arms which ligate to each other
without a DNA insert encode the beta-galactosidase enzyme across the ligation site. The
presence of an insert disrupts the galactosidase sequence. The host bacteria, XLI-Blue
MRF', was infected with the packaging reaction and plated in the presence of IPTG and
~-galactosidase.

Lambda Zap II:A. actinomycetemcomitans expression libraries were

found to have relatively high titers of approximately Ix107 PFU/ug DNA. Less than 10%
of the plaques showed beta-galactosidase activity, demonstrating a recombination
efficiency of >90%.
We next investigated whether the insert sizes in the phage library matched the
expected size range. PCR amplification of random recombinant clones was done using
M13forward and M13reverse primers and published PCR protocols. Results in Figure 6
show bands were diverse sizes between 200-1400 bp consistent with random fragments.
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Further, to confirm diverse portions of the A. actinomycetemcomitans genome were
cloned, Ten inserts were sequenced and aligned to the A. actinomyctemcomitans genome.
Inserts appeared to be randomly selected from different areas of the bacterial
chromosome. Since phage that are packaged in vitro are not very stable, half the library
was immediately amplified and stored.
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Figure 6. Size Determination of Expression Library Inserts

1000 bp
800 bp
600 bp

Figure 6. Size Determination of Expression Library Inserts. Phage particles from "white"
(~-gal

activity negative) plaques were directly peR amplified using Amplifier Forward

and Reverse primers that encompass the EcoR1 insert site. Negative inserts yield a 160
bp band. Bands range in size from 200-1400 bp.
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Immunoscreening Genomic DNA Lambda Phage Expression Libraries
Western Blot Analysis of Individual Serum Antibody Responses to Bacteria
Western blot analysis of bacteriallysates was used to determine the relative
antibody titer in each human serum sample. This step ensures that the original serum
samples were immunoreactive to a broad range of A. actinomycetemcomitans antigens
and had sufficient antibody titers for immunoscreening. Bacteriallysates for E.coli, P.
gingivalis, or A. actinomycetemcomitans were run on SDS-PAGE gels and transferred to

PVDF membranes. Membranes were probed overnight with individual serum aliquots
(1 :500 dilution) followed by goat a-human Ig secondary antibody. CNIDAB substrate

was added for visualization of results. Antibody titers in some sera (e.g. serum samples
#3 and #4) were found to be too low for use in screening of A. actinomycetemcomitans
libraries. Instead, high titer sera (e.g. serum samples #1, #2, and #8) were chosen to be
used for screening of the expression libraries.
The antigenic bands identified differed between bacterial species. A.
actinomycetemcomitans often had more antigenic bands and more intense staining than P.
gingivaiis, but not always. Serum from different individuals recognized different

antigenic proteins in A. actinomycetemcomitans extracts, with different intensities. Thus,
the high variability in individual serum antibody response must be taken into
consideration when choosing sera for screening of expression libraries. This is
un surprising considering it strongly supports the project's approach which is based on the
idea that individuals have different profiles of antibodies.
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Figure 7. Western Blot Analysis: Individual Serum Antibody Responses to Bacteria
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Fiqure 7. Western blot analysis of individual serum antibody responses to oral bacteria.
Iflg of total bacterial lysate for E.coli (E), P. gingivalis (P), or A. actinomycetemcomitans
(A) was run on a SDS-PAGE gel and transferred to PVDF membrane. Membranes were
probed overnight with serum from different individuals using aliquots at 1:500 dilution.
Goat a-human total Ig at 1: 10k dilution secondary antibody was used and CNIDAB
substrate was added for visualization of results. Responses to A. actinomycetemcomitans
are variable between patients with regard to banding patterns and antibody titers.
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Immunoscreening A. actinomycetemcomitans Genomic DNA Libraries
Membranes from ZAPII: A. actinomycetemcomitans plates were incubated with
serum pools, 1:500 in blocking buffer, overnight before incubation for 1 hour with
secondary antibody goat a-human total Ig (HRP conjugated) followed by CN:DAB for
visualization. In Figure 8A, an individual immunoreactive plaque (box) is seen among
approximately 200 plaques in panel field. Plugs from immunoreactive plaques were
picked and re-screened for clone isolation. Secondary plating, Figure 8B, increased the
percentage of positive clones while tertiary plating (Figure 8C) allowed for isolation of
pure clones. As can be seen in Figure 8, each successive plating increased the percentage
of positive clones. Each blot also included a positive control spot of crude A.
actinomycetemcomitans lysate.

About 100,000 plaques have been screened and 72 immunoreactive clones have
been isolated. Of the 72 immunoreactive clones picked, 26 made it through primary,
secondary, and tertiary screening.
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Figure 8. Serum Screening for Immunoreactive Plaques and Clone Isolation
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Figure 8. Serum Screening for Immuno-reactive Plaques and Clone Isolation. Membranes
from Lambda ZAPII: A. actinomycetemcomitans plates were incubated with serum
pools, 1:500 in blocking buffer (5% milk in TBST), overnight before incubation for 1
hour with HRP conjugated secondary antibody goat a-human total Ig at 1: 10,000. In
panel A, an individual immunoreactive plaque (box) is seen among -200 plaques in panel
field. Immunoreactive plaques were picked and re-screened for clone isolation.
Secondary screening (panel B) of the plaque from panel A exhibits an increased ratio of
reactive plaques (dark spots) to non-reactive plaques (light spots). Panel C shows that all
the plaques in this tertiary screen are positive.
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Identifying Positive A. actinomyctemcomitans Gene Sequences
Each plasmid generated from identified immunopositive tertiary plaques was
sequenced to identify the proteins expressed. This study used the Nucleic Acids Core at
the University of Louisville for sequencing. A. actinomycetemcomitans clone sequences
were compared to the published genome using BLAST on the ICVI website
(cmr.jcvi.org), on the ORALGEN website (www.oralgen.lanl.gov), or on the NIH
website (blast.ncbi.nlm.nih.gov). Figure 9 shows a typical BLAST analysis of the DNA
sequence of an antigenic peptide found through tertiary screening of clones. Analyses
compare the nucleotide sequence of the clone with that found in the database and provide
a detailed description of proteins with significant homology.
From the sequences, the insert DNA and 7 codons upstream of the EcoRI insert
site were blasted using the TIGR-CMR BLAST database to identify A.

actinomycetemcomitans genes encoded within the insert. The BLASTx option was
utilized to insure that the insert was in the correct reading frame. All sequenced tertiary
screened clones were in the correct reading frame. The genes identified are listed in Table
1. Table 2 includes more detailed information about the A. actinomycetemcomitans genes.
Column 1 of Table 2 gives the Los Alamos National Laboratories gene number. Column
2 gives the gene name. Columns 3,4, and 5 give the nucleotide identity, gaps in the
sequence identification and E value, respectively. Columns 5, 6, and 7 give the protein
definition, gene length and the functional class of the protein.
Of these, 7 antigenic peptide sequences appeared to be similar to others we had
identified, while the remaining 19 antigenic peptide sequences appeared unique. Of the
19 unique antigens identified, eight appear to be proteins displayed on the bacterial cell
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wall, while the remaining eight appear to be protoplasmic proteins. 17 of the 19 unique
antigens have not been studied in A. actinomycetemcomitans and were instead found
through homology to proteins in other species.
The identity of the 19 unique antigens was determined by a comparative analysis
of their nucleotide sequences. The comparative analysis showed an 84% or greater
homology between the sequence of clones and the sequence in the database. 18 of the 19
unique antigens showed a homology of 93% or greater. Genes ranged in length from 279
bp to 3168 bp.

36

Figure 9. Blast Search of A. actinomycetemcomitans Clone Sequence
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Figure 9. Blast Search of A. actinomycetemcomitans Clone Sequence. This is an example
of a BLAST analysis of an antigen found through tertiary screening of clones. The
BLAST results show that the antigenic protein is most likely a conserved hypothetical
protein that has not been studied in A. actinomycetemcornitans. 686 bp out of 687 bp
were identical to the database' s sequence of the conserved hypothetical protein. All
tertiary screened clones had a homology with the database of greater than or equal to
84%.
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Table 1. Antigenic Genes of Aggregatibacter actinomycetemcomitans Identified
Through the Use of Whole Genome Protein Expression Libraries
Novel*
hgpA

Hemoglobin binding protein A

No

hgpAb

Hemoglobin binding protein A

No

fecS

Iron (III) dicitrate-binding periplasmic

Yes

ftsA

Cell division protein A

Yes

IpeA

Phosphoheptose isomerase

Yes

acrB

Acriflavine resistance protein

Yes

atpA

ATP synthase Fl, subunit alpha

Yes

mutL

DNA mismatcvh repair protein

Yes

amiS

N-acetylmurmoyl-L-alanine amidase II

Yes

dsbA

Thiol-disulfide interchange protein

Yes

cbiQ

Cobalt membrane transport protein

Yes

rplY

50S ribosomal protein L25

Yes

hipS

Lipoprotein

Yes

pbpG

Penicillin-binding protein

Yes

Unknown 1

Hypothetical protein

Yes

pykA

Pyruvate kinase II

Yes

Unknown 2

Conserved hypothetical protein

Yes

hypF

Hydrogenase maturation protein

Yes

Unknown 3

Conserved hypothetical protein

Yes
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Table 2. A.a. Antigen Table

Gene
Number
LANL
AA01751

AA02101
AA01751
AA01751

Nucleotide
Gene Name Identity
686/687 (99%)
CbiK

pbpG

Gaps
E Value
1/687 (0%)

Definition
o Putative peri plasmic binding protein

240/283 (84%) 4/283 (1%) 2.00E-57 Penicillin-binding protein 7
213/217 (98%) 3/ 217 (1%) 1.00E-l04 Conserved Hypothetical Protein
o Conserved Hypothetical Protein
464/ 466 (99%) 21466 (0%)
690/699 (98%)

hgpA, hgbA,
AA00763 hamA
AAOl341 acrB

269/278 (96%) 4/278 (1%) 1.00E-126 Hemoglobin binding protein A
o Acriflavine resistance protein
370/370 (100%)
0

AA01588
AA02099
AA01756
AA00830
AA01586

718/722
170/ 178
400/ 401
218/ 221
469/474

amiB
rplY
cbiQ
ftsA
mutl

AA00795 lecB, leoB

(99%)
(95%)
(99%)
(98%)
(98%)

1421147 (96%)

4/699( 0%)

o Hydrogenase maturation protein

AA02682 hypF

o N-acetylmuramoyl-l-alanine amidase II
(3%) 4.ooE-62 50S ribosomal protein L25
o cobalt membrane transport protein
(0%)
(1 %) 1.00E-l09 cell division protein A
o DNA mismatch repair protein
(0%)
iron (III) dicit rate-binding periplasmic
2.ooE-64 protein precursor

21722 (0%)

7/178
1/401
3/221
4/474

Gene
Length
Functional Class
759 Cobalt chelatase protein
Cell envelope; murein
sacculus and
279 peptidoglycan

Central intermediary
2283 metabolism
Transport and binding
1785 proteins ; cations
3168 Drug sensitivity
Cell envelope; murein
sacculus and
1485 peptidoglycan
285 Translation
672
1278 cell division
1848 DNA repair

A. Sequences Producing Significant
Alignments
putative ABC-type Co2+ transport

penicillin-binding protein 7

Hydrogenase maturation protein

Hemoglobin binding protein
acriflavine resistance protein

N-acetylmuramoyl-l-alanine amidase II
rpl25
cell division protein ftsA
Mutl

0\
('()

Table 2. continued
A.a. Antigen Table

Gene
Number
LANL

Gene
Name

Nucleotide
Identity

Gaps

E Value

Definition

AA00795 fecB, feoB

1421147 (96% )

iron (III) dicit rate-binding peri plasmic
2.00E-64 protein precursor

hgpA,
AA00764 hamA

193/198 (97%) 4/198 (2%)

2.00E-88 Hemoglobin binding protein A

AA02214 pykA

718n35 (97%)

6/745 (0%) O.OOE+OO pyruvate kinase II

Gene
Length

Functional Class

A_ Sequences Producing Significant
Alignments

Transport and binding
891 proteins, ABC superfamily Beta-D-galactosidase (Iacl)
TonB-<lependent receptor, putatiw.
Transport and binding
Different LANL Gene Number than
420 proteins; cations
Tertiary 6
Central intermediary
metabolism (glycolysis &
gluconeogenesis - Carbon
1506 fixation)
PykA

o
IpcA,
AA00860 gmhA, isn
AA01751

268/271 (98%)
0 1.00E-146 phosphoheptose isomerase
597/599 (99%) 21599 (0%) O.OOE+OO Conserved Hypothetical Protein

AA02100 hlpB
AA02613

3921396 (98%)

AA01748 dsbA
hgpA,
hgbA,
AA00763 ham A
hgpA,
hgbA,
AA00763 hamA
hgpA,
hgbA,
AA00763 hamA
AA01486 atpA

AA02115

558/596 (93%) 6/596 (1 %) O.OOE+OO lipoprotein
1/396 (0%) O.OOE+OO Conserved Hypothetical Protein
248/248 (0%)

o 1.00E-139 thiol:disulfide interchange protein

401/416 (96%)

8/416 (1 %) O.OOE+OO Hemoglobin binding protein A

553/560 (98%)

4/560 (0%) O.OOE+OO Hemoglobin binding protein A

4/433 (0%) O.OOE+OO Hemoglobin binding protein A
617/624 (98%) 6/624 (0%) O.OOE+OO ATP synthase F1, subunit alpha
Hypothetical protein (Also possible
AA01289 & AA01075 hypothetical
378/380 (99%)
0 O.OOE+OO proteins with same (0) E-value)

Cell enwlope, surface
582 polysaccharides
759 Unknown

-.:::t

GmhA
Same as #T1

663 Cell enwlope; membranes Lipoprotein HlpB
783 Unknown
Unknown
Translation; Protein
669 modification
Thiol:disulfide interchange protein

Transport and binding
1785 proteins; cations

4221433 (97%)

1539 Enery metabolism

384 Unknown

A TP synthase alpha chain

Integrase

DISCUSSION

A novel research technique was developed to discover antigenic proteins from the
periodontal bacterium, A. actinomycetemcomitans. The technique takes advantage of the
the high gene density of the bacterial genome (i.e., no introns), the efficiency of
transformation by lambda vectors, and the high level of protein expression in plaques
created by lambda phage. After generating A. actinomycetemcomitans genomic DNA
expression libraries, the libraries were plated and then probed using human serum to
identify periodontal antigens. Identified antigens then undergo additional screenings to
confirm and define antigenicity. Bacteriophage encoding antigens were converted to
plasmids for archiving and sequenced for gene identification.
The A. actinomycetemcomitans whole genome protein expression libraries were
made using the Lambda ZapII library construction kit. Libraries consisted of random
sized inserts correlating to a range of about 400 to 1400 bp in size. The key insight that
allowed this project to proceed is that complex libraries can be screened from small
fragments of genomic DNA with an efficiency that will theoretically provide unbiased
and complete coverage of all bacterial antigens. My results demonstrated that the
unbiased A.actinomycetemcomitans genomic DNA expression libraries expressed A.
actinomycetemcomitans proteins at a high level that allowed subsequent screening with
human serum.
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Individual patient serum antibody responses to oral bacteria played a large part in
the detection of bands by Western blotting. Individual serum antibody responses were
highly variable and had to be taken into consideration when choosing sera for screening
of expression libraries (Figure 7). Pooling of the most antigenic sera as determined by
staining intensity and band dispersion provided optimum results and resulted in a greater
number of positive plaques.
Immunoscreening of A. actinomycetemcomitans libraries allowed the
identification of antigenic plaques which were subsequently isolated and sequenced.
Using this technique, 26 antigens were identified, 19 of which were unique. 17 of the 19
novel antigens have not been studied in A. actinomycetemcomitans.
The new antigens include a variety of functions, being involved with metabolism,
in the hemoglobin binding family, responsible for drug resistance, or of unknown
functions. Two of the proteins are recognized as virulence factors, pbpG, a penicillinbinding protein (Keseler, 2005) and integrase (Chen, 2009), which mediates integration
of a DNA copy of the microbe genome into the host chromosome. Further, eight of the
antigens are found extracellularly while eight are only found intracellularly. The presence
of antibodies to cell wall antigens may indicate the individual has either current or recent
active infection. The presence of antibodies to cytosolic antigens may indicate that
bacteria are being effectively destroyed, making cytosolic proteins available to the
immune response. The variety of different antigenic proteins suggests that a clustal
analysis of antibodies as biomarkers may be a more productive approach than functionbased analysis. That is, identification of a profile of multiple antibodies present in an
individual may relate to the future progression of disease.
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Over the last decade, approximately 23 A. actinomycetemcomitans antigens have
been published where assignment to the bacterial gene was possible, a necessary step for
identification of the antigenic protein. The novel antigens reported here have significantly
increased the number of known A.actinomycetemcomitans antigenic genes. The limited
overlap between these antigenic clones and the previously reported antigenic genes
suggests that there are large numbers of uncharacterized antigens.
The novel immunoscreening technique is effective in identifying periodontal
antigens. Future studies should use additional human sera to identify any other A.
actinomycetemcomitans periodontal antigens. The identification of reactive A.
actinomyctemcomitans bacterial antigens opens new approaches to the diagnosis and

treatment of periodontal disease. Among the new approaches are vaccine candidates,
pharmaceutical drug discovery assays, and serodiagnostic assays for research and clinical
purposes. To attain these goals, additional studies will need to correlate the presence of
specific antibodies to the progression of periodontal disease.
Identification of A. actinomyctemcomitans antigens may suggest vaccine
candidates (Etz, 2002). For example, by identifying the antigens with the strongest
association with mild disease or that protect from disease, one could develop novel
vaccine candidates for immunization to prevent periodontal disease in susceptible
populations (Page, 2000). Such a vaccine could reduce morbidity associated with
periodontal disease and linked systemic diseases.
Additionally, the identification of reactive A. actinomyctemcomitans antigens may
have utility as a diagnostic tool. Currently, characterization of periodontitis is
predominantly based on clinical findings. However, a laboratory test has the potential to
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provide a prognostic serodiagnosis predicting the probability of future severe disease or
the patient's response to treatment. This would direct the clinician's treatment decisions.
For example, a patient with a high probability of future severe disease may be treated
more aggressively than one with a low probability of future disease.
Microarrays could potentially provide such a diagnostic tool. Protein micro arrays
provide a multiplex approach to detect proteins, monitor their expression levels, and
investigate protein interactions and functions. Through automation, protein microarrays
can carry out large numbers of determinations in parallel, achieving efficient and
sensitive high throughput protein analysis. Determinations can be carried out with
minimum use of materials while generating large amounts of data. Research with protein
micro arrays includes protein-antibody, protein-protein, protein-ligand or protein-drug,
enzyme-substrate screening and multianalyte diagnostic assays.
Antigen micro arrays are a subset of protein arrays that provide a rapid, highthroughput approach to serodiagnosis. Antigen array technologies enable large-scale
profiling of the specificity of antibody responses against autoantigens, tumor antigens and
microbial antigens. They provide insight into pathogenesis, and will enable development
of novel tests for diagnosis and guiding therapy in the clinic (Robinson, 2006). Multiple
putative antigen proteins are spotted on the array, and are probed with patient serum to
define the patient's specific antibody profile or combinatorial pattern. Bacarese-Hamilton
(Bacarese-Hamilton, 2004) found strong concordance between antigen microarrays and
ELISA, the most common technique for serodiagnosis of microbial infections. This
proof-of-principal for antigen micro array-based serodiagnosis of infectious disease opens
up new opportunities to identify multiple specific antibodies in a patient's serum.
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The identification of reactive A. actinomyctemcomitans bacterial antigens is a key
component to developing a serodiagnostic assay for periodontal disease. This thesis
research is the first step in developing such an assay. Identified antigens could be
screened by microarray to compare antigen profiles of individual periodontitis patients
and control subjects. Such profiles may be invaluable in the positive identification of
antigens which could either confer resistance to periodontitis or contribute to disease.

In summary, we developed an A. actinomycetemcomitans expression library and
immunoscreening method in order to identify specific bacterial protein antigens that elicit
humoral immune responses during periodontal disease infection. Using this technique, 19
A. actinomycetemcomitans antigens recognized by some humans were identified. These

novel antigens could have diagnostic utility as well as immunization potential for the
diagnosis and prevention of periodontal disease.
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